Scientists at Aurelia Bioscience have been involved in the design and development of many drug discovery projects incorporating complex biology and implementing a suite of assays designed to identify “active” compounds and improve their biological properties.
These properties include potency, selectivity and cell penetration. This work has involved consultation with project and target biologists to determine the most appropriate assay for the initial screen and any subsequent assays that many be required to remove compounds with unwanted off target effects, cross-over to other target family members as well as false positive compounds i.e. those that are active as a consequence of interacting with the reporting technology rather than the target directly.
Iterative Cyclical Screening (Lead Identification – LI)Service Iterative Biology Screening in a Cyclical manner to clients chemical synthesis needsDescription Assay already developed by Aurelia Bioscience or client, pharmacologically characterised for compound testing and used regularly to screen compoundsDeliverables Delivery of activity data generated on each compound in the assay of choice on a cyclical basis to XC50 level of screening e.g. weekly, bi-weeks or monthly. Compounds synthesised by client for an iterative test cycle at Aurelia BiosciencePrice POA
Complete Drug Discovery Project – Assay Development to LIService Complete Discovery ProjectDescription Based around one target and involving assay development, validation, HTS, development of downstream assays, iterative screening of hits in cyclical manner against assays in the project cascade.Deliverables Fully developed and validated assays, data on all compounds screened in HTS assay and subsequent compounds synthesised and screened in appropriate assays. Consultancy and management of bio-reagent provision by sub-contractors as necessary. Frequent and detailed communication between Aurelia Bioscience and client.Price POA
We are very experienced in the respiratory and inflammatory biology research area and we have designed assays for other research areas including oncology and CNS-pain.
1,100 compounds IC50 against two cell-based assays then hits-to-lead SAR program in collaboration with chemistry CRO to generate novel IP
- Use their proprietary ‘Molecular Pharmacology’ software used to ‘weight’ biological pathways and interactions to identify key nodes essential for biological processes
- Identify hit compounds from a selected set of 1,100 compounds
- Screen the 1,100 compounds in two cell-based assays designed to detect antiproliferative effects then IC50 in both assays and a selective cyto-toxicity assay
- Generate a novel IP position with new compounds in a twelve month period
Aurelia Bioscience’s role:
Develop two robust cell assays to determine cellular differentiation and cyto-toxicity
Screen 1,100 compounds as dose-response through both assays
Collaborate with Horizon Discovery on development of CRISP cell lines for evaluation
Work with Fidelta, the chemistry CRO employed by the client, to adhere to a one week design-make-test cycle for compound progression throughout the course of the project